amoxicillin
/ Generic mfg.
- LARVOL DELTA
Home
Next
Prev
1 to 25
Of
7753
Go to page
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
December 13, 2025
Amide-functionalized cellulose derived from sugarcane bagasse for efficient removal of amoxicillin and moxifloxacin from water.
(PubMed, Int J Biol Macromol)
- "The maximum adsorption capacities (qmax) obtained under optimized experimental condition were 473.46 mg/g and 435.38 mg/g for AMX and MOX respectively. Owing to low cost and high efficiency, amide functionalized cellulose obtained from sugarcane bagasse could be used as an alternative adsorbent to expensive commercial adsorbents for the removal of antibiotics and other pollutants from water."
Journal
December 12, 2025
Tailoring Nanoparticle Surfaces Empowered by Multivariate Techniques for Detection of Multiple Antibiotic Fingerprints in Real Samples Using Hand-Held Colorimetric Signal Readout.
(PubMed, ACS Appl Mater Interfaces)
- "With 100% accuracy, the sensor array successfully discriminates between eight antibiotics (amoxicillin, azithromycin, neomycin, streptomycin, chloramphenicol, ofloxacin, fluconazole, and ciprofloxacin), with detection limits ranging from 1.7 to 8.3 μM. Further, for the real-time applications, we have developed prototypes for colorimetric analysis and also modified the previously developed 96-well plate reader, which functions similarly to the UV-visible absorption spectrophotometer. These on-site sensing methods, with straightforward preparation, quick response, exceptional sensitivity, and consistently stable high-throughput signal output, show significant potential for practical use in food forensics and for environmental remediation."
Journal
December 12, 2025
Performance of the Self-Controlled Case Series With Active Comparators for Drug Safety Signal Detection Using the Clinical Practice Research Datalink (CPRD).
(PubMed, Pharmacoepidemiol Drug Saf)
- "Using a carefully designed reference set of drug-outcome pairs well suited to the study design, the SCCS performed moderately well for signal detection in CPRD. Whilst active comparators effectively reduced confounding by indication, they also reduced the number of correctly identified positive controls, due to a reduction in power. We showed some evidence that SCCS is able to highlight SDRs before they were present on labels."
Journal
December 12, 2025
Antibacterial activity of Cerium Oxide Nanoparticles: a systematic review and meta-analysis study.
(PubMed, Nanomedicine (Lond))
- "Compared to conventional antibiotics, CeO2 NPs were generally less effective (SMD = -2.846, p < 0.0001) but performed comparably to Amoxicillin, Streptomycin, Linezolid, and Clindamycin. CeO2 NPs demonstrate significant broad-spectrum antibacterial activity, suggesting potential against antibiotic-resistant bacteria. Future research should explore synergistic effects with standard antibiotics."
Journal • Retrospective data • Review • Infectious Disease
December 12, 2025
Toxic Epidermal Necrolysis Induced by First-Line Helicobacter pylori Eradication Therapy: A Case Report.
(PubMed, Korean J Helicobacter Up Gastrointest Res)
- "Here, we report a fatal case of TEN in an 80-year-old patient who developed diffuse bullous eruptions and multiorgan failure following first-line Helicobacter pylori eradication therapy with a proton pump inhibitor, amoxicillin, and clarithromycin. Despite intensive care, including corticosteroids and supportive treatment, the patient died of sepsis and progressive organ failure. This case highlights the need for early detection of severe cutaneous adverse reactions, particularly in elderly patients receiving H. pylori eradication therapy."
Journal • Critical care • Infectious Disease • Septic Shock • Steven-Johnson Syndrome
December 12, 2025
Docosahexaenoic Acid-Driven Metabolic Reprogramming as an Attractive Anti-Infection Strategy to Potentiate β-Lactam Antibiotic Efficacy.
(PubMed, Research (Wash D C))
- "Furthermore, to enhance the pharmacodynamic performance and stability of DHA, amoxicillin and DHA co-loaded nanoemulsions (Amo/DHA-NEs) were prepared via high-energy emulsification. Intriguingly, we found that Amo/DHA-NEs effectively rescued MRSA-induced infections in the murine infection models, as evidenced by the superior bacterial clearance and mitigated inflammation. Collectively, this work reveals a potentially exploitable link between DHA-driven metabolic reprogramming and β-lactams resistance, and we propose combination therapies of DHA and β-lactams targeting the emerging threat of MRSA infections."
Journal • Infectious Disease • Inflammation • Metabolic Disorders
December 12, 2025
In vitro efficacy of sulbactam/durlobactam combined with β-lactam antibiotics in Australian Mycobacterium abscessus isolates.
(PubMed, J Antimicrob Chemother)
- "Sulbactam/durlobactam significantly increased susceptibility to oral and intravenous β-lactam antibiotics in the form of cefuroxime, cefuroxime/amoxicillin and meropenem against clinical isolates of M. abscessus. This study also found significant differences in susceptibility to β-lactam antibiotics dependent on the culture media used, highlighting that the optimal culture methods for determining MIC in M. abscessus remains uncertain. Future in vivo studies are required to determine whether the in vitro efficacy of the β-lactam combinations studied could result in clinical efficacy for M. abscessus disease."
Journal • Preclinical
December 11, 2025
Determination of antimicrobial resistance pattern among post-operative orthopedic implant patients in a tertiary care hospital: A retrospective study.
(PubMed, Int J Clin Pharmacol Ther)
- "The critical challenges of antimicrobial resistance in orthopedic implant-related infections have been highlighted. Urgent institutional and policy level interventions are required for implementation of stringent infection control protocols and robust antibiotic stewardship programs to prevent a post-antibiotic crisis."
Journal • Retrospective data • Infectious Disease • Orthopedics
December 11, 2025
Nanocurcumin: An Innovative Strategy to Combat Virulence and Methicillin Resistance in Staphylococcus aureus Isolated from Burn Wounds.
(PubMed, Iran J Med Sci)
- "The 50 selected isolates were resistant to cefoxitin, amoxicillin, benzylpenicillin, ampicillin/sulbactam, piperacillin/tazobactam, cloxacillin, oxacillin, and azithromycin. No significant changes were seen in fnbA and ftsZ. Nanocurcumin inhibits S. aureus virulence and resistance genes, reducing biofilm formation and toxin production, but lacks effect on fnbA and ftsZ, requiring further research."
Journal • Infectious Disease
December 11, 2025
Procedural Challenges in Soil Sample Preparation for Pharmaceuticals Analysis.
(PubMed, Molecules)
- "Our results indicate that some compounds can be eliminated even up to 100% (including amoxicillin, ampicillin, and lincomycin) during ultrasonication and/or filtration. This study demonstrates that even problematic compounds, despite their low recovery, can be analyzed by the addition of isotopically labelled internal standards with acceptable accuracy. This finding is particularly important for environmental monitoring, where trace-level detection of pharmaceutical residues is often challenged by matrix complexity and analyte instability."
Journal
December 11, 2025
Patient with Inflammatory Bowel Disease in a Dental Office-Which Antibiotic to Choose?-Narrative Review.
(PubMed, J Clin Med)
- " The available evidence suggests that first- and second-line dental antibiotics-amoxicillin, ampicillin, and clindamycin-carry the highest risk of CDI. Tailored, microbiome-conscious antibiotic strategies are essential in dental management of IBD patients. Further clinical research is needed to develop evidence-based guidelines and validate promising adjunctive approaches."
Journal • Review • Crohn's disease • Gastroenterology • Gastrointestinal Disorder • Immunology • Infectious Disease • Inflammation • Inflammatory Bowel Disease • Ulcerative Colitis
December 11, 2025
PRO-EXOD: Antibiotic Prophylaxis After Simple Tooth Extraction in Immunosuppressed Patients With Autoimmune Rheumatic Diseases
(clinicaltrials.gov)
- P4 | N=352 | Not yet recruiting | Sponsor: University of Sao Paulo General Hospital
New P4 trial • Immunology • Infectious Disease • Rheumatology
December 11, 2025
Increasing the pneumonia treatment coverage among children under 5 years old through 'Enhanced Management of Pneumonia in the Community': implementation research protocol.
(PubMed, BMJ Open)
- "The current implementation research using both qualitative and quantitative data collection methods will assess the feasibility and acceptability of iCCM-trained HSAs managing chest indrawing pneumonia and fast-breathing pneumonia in children under 5 with oral amoxicillin at the community level in district Kasungu using the existing district health system...Ethical approval was obtained from the National Health Research Sciences Committee and the WHO Ethics Committee. The implementation research findings will be disseminated to national-level stakeholders and specifically targeted at District Health Offices, which are responsible for implementing the interventions."
Journal • Infectious Disease • Pediatrics • Pneumonia • Respiratory Diseases
December 11, 2025
Fourteen-and Ten-Day Tegoprazan-Amoxicillin Dual Therapy vs. Bismuth Quadruple Therapy for Helicobacter pylori Eradication-A Noninferiority, Multicenter, Randomized Controlled Trial.
(PubMed, J Gastroenterol Hepatol)
- "The eradication rate of the 14-THA group is > 90%, which is not inferior to the current bismuth-containing quadruple regimen, with a favorable safety profile. However, the efficacy of the 10-THA dual therapy is unacceptable."
Head-to-Head • Journal • Infectious Disease
December 09, 2025
Eradication Rates of Empiric Helicobacter pylori Treatment Regimens by Race/Ethnicity in a Predominantly Immigrant U.S. Population.
(PubMed, Helicobacter)
- "Empiric bismuth quadruple therapy had the highest eradication rate while metronidazole and levofloxacin triple therapies had the lowest. Eradication rates may thus serve as a surrogate clinical endpoint when choosing empiric therapies."
Journal • Retrospective data • Infectious Disease
December 09, 2025
Comparison between optimized bismuth quadruple therapy and standard clarithromycin-based triple therapy for first-line Helicobacter pylori eradication: a double-blind randomized controlled trial.
(PubMed, Lancet Reg Health Am)
- P4 | "We compared optimized bismuth quadruple therapy: esomeprazole 40 mg three times a day, amoxicillin 1 gr three times a day, metronidazole 500 mg three times a day, and bismuth subsalicylate 369 mg three times a day for 14 days, and standard triple therapy omeprazole 20 mg twice a day, amoxicillin 1 gr twice a day, and clarithromycin 500 mg twice a day for 14 days in a Chilean population. Optimized bismuth quadruple therapy is a reliable and safe empiric eradication therapy, especially in areas with high clarithromycin resistance. FONDECYT (1230504 AR); ANID-FONDAP (152220002 AR); Horizon 2020 program of European Union (825832 AR); ANID-FONDAP (15130011)."
Journal • Gastric Cancer • Gastroenterology • Gastrointestinal Disorder • Infectious Disease • Oncology • Peptic Ulcer • Solid Tumor • CYP2C19
December 09, 2025
Study to Evaluate the Efficacy and Safety of DWP14012-based Triple Therapy in Eradication of Helicobacter Pylori
(clinicaltrials.gov)
- P3 | N=461 | Completed | Sponsor: Daewoong Pharmaceutical Co. LTD. | Recruiting ➔ Completed | Trial completion date: Jun 2026 ➔ Apr 2025 | Trial primary completion date: Jan 2026 ➔ Apr 2025
Trial completion • Trial completion date • Trial primary completion date • Infectious Disease
December 09, 2025
NextGen - Clinical Implication of Next Generation Sequencing
(clinicaltrials.gov)
- P4 | N=100 | Recruiting | Sponsor: Wake Forest University Health Sciences | Trial completion date: Dec 2026 ➔ Dec 2028 | Trial primary completion date: Dec 2026 ➔ Dec 2028
Biomarker • Trial completion date • Trial primary completion date • Infectious Disease • Nephrology
December 08, 2025
Novel drug-loaded nano-polymer comparison: amoxicillin between ceftriaxone for MCF-7 breast cancer cytotoxicity.
(PubMed, J Biomater Sci Polym Ed)
- "This work establishes a scalable nano-polymer platform for antibiotic repurpose, identifies ceftriaxone as a superior candidate for breast cancer therapy, and provides a critical mechanistic bridge between drug chemistry and tumor biology. With its established clinical safety, this ceftriaxone-based system represents a viable candidate for rapid translation to in vivo studies."
Journal • Breast Cancer • Oncology • Solid Tumor
December 08, 2025
Targeted LC-MS/MS method for quantifying respiratory pharmaceuticals in wastewater.
(PubMed, Environ Sci (Camb))
- "Application to 12 neighborhood-level wastewater samples detected 9 of the 10 target compounds, with 6 (albuterol, amoxicillin, azithromycin, cetirizine, diphenhydramine, and fexofenadine), detected above their quantification limits. Fexofenadine was the most abundant, reaching 3309 ng L-1. This robust, low-volume, high-throughput LC-MS/MS method enables the reliable detection of respiratory pharmaceuticals in wastewater, supporting WBE applications for pharmaceutical use surveillance."
Journal • Respiratory Diseases
December 08, 2025
Valacyclovir for Acute Apical Abscess Pain: A Randomized, Placebo-Controlled, Double-Blind Study.
(PubMed, J Endod)
- "Valacyclovir shows promise as an adjunctive therapy for early pain relief in patients with acute apical abscesses."
Clinical • Journal • Infectious Disease • Pain
December 06, 2025
Single-Entity Dual-Emissive MOF Platform for Reliable Ratiometric Point-of-Care Detection of Amoxicillin Residues.
(PubMed, Anal Biochem)
- "Additionally, a smartphone-assisted visual detection method using RGB analysis via the Color Grab App was developed, enabling portable and on-site quantification. This self-referencing Eu-MOF is inherently stable, recyclable, providing consistent signals and making it highly effective for pharmaceutical applications."
Journal
December 05, 2025
Use of fluoroquinolones and the risk of seizures: a population-based cohort study.
(PubMed, Clin Microbiol Infect)
- "Our large cohort study showed that fluoroquinolones were not associated with the risk of seizures overall. An increased risk among patients with chronic kidney disease is possible."
Journal • Chronic Kidney Disease • CNS Disorders • Epilepsy • Nephrology • Renal Disease
December 04, 2025
Antimicrobial Resistance Patterns and Prevalence of Salmonella Species in Blood Samples: Insights From a Tertiary Care Center in Nepal.
(PubMed, Interdiscip Perspect Infect Dis)
- "No multidrug resistance was observed, and all isolates were susceptible to third- and fourth-generation cephalosporins (e.g., cefixime, ceftriaxone, and cefepime) and β-lactamase inhibitors (e.g., piperacillin-tazobactam).Salmonella Paratyphi showed 100% sensitivity to ampicillin, amoxicillin, and cotrimoxazole, while susceptibility to chloramphenicol was high for both S. Typhi (88.9%) and S. Paratyphi (92.9%)...High resistance to ciprofloxacin and gentamicin was observed, while susceptibility to ampicillin, chloramphenicol, and cotrimoxazole re-emerged, suggesting their potential for reintroduction in treatment. No multidrug resistance or resistance to third- and fourth-generation cephalosporins (e.g., cefixime, ceftriaxone, cefepime) and β-lactamase inhibitors (e.g., piperacillin-tazobactam) was noted, supporting their reliability for empirical therapy. These findings underscore the need for ongoing antimicrobial surveillance to guide effective treatment strategies."
Journal • Infectious Disease
December 04, 2025
Community-acquired pneumonia in Indonesian children: insights into diagnosis, treatment compliance, and healthcare provider challenges.
(PubMed, Arch Public Health)
- "This study highlights significant inconsistencies in paediatric CAP management among healthcare providers in Indonesia and emphasises the need for targeted training to enhance guideline compliance and improve patient outcomes."
Compliance • Journal • Infectious Disease • Pediatrics • Pneumonia • Respiratory Diseases
1 to 25
Of
7753
Go to page
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311